Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0C7RV
|
|||
Former ID |
DNC003421
|
|||
Drug Name |
SR12813
|
|||
Synonyms |
SR 12813; 126411-39-0; SR-12813; SR12813; CHEBI:77317; GW 485801; CHEMBL458767; [2-(3,5-DI-TERT-BUTYL-4-HYDROXY-PHENYL)-1-(DIETHOXY-PHOSPHORYL)-VINYL]-PHOSPHONIC ACID DIETHLYL ESTER; 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol; Tetraethyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethenyl-1,1-bisphosphonate; tetraethyl [2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethene-1,1-diyl]bis(phosphonate); [[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethenylidene]bis-phosphonic acid tetraethyl ester; SRL; 1ilh; AC1L9JHO
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Arteriosclerosis [ICD-11: BD40; ICD-9: 440] | Terminated | [1], [2] | |
Structure |
Download2D MOL |
|||
Formula |
C24H42O7P2
|
|||
Canonical SMILES |
CCOP(=O)(C(=CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C)P(=O)(OCC)OCC)OCC
|
|||
InChI |
1S/C24H42O7P2/c1-11-28-32(26,29-12-2)21(33(27,30-13-3)31-14-4)17-18-15-19(23(5,6)7)22(25)20(16-18)24(8,9)10/h15-17,25H,11-14H2,1-10H3
|
|||
InChIKey |
YQLJDECYQDRSBI-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 126411-39-0
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
822789, 827882, 7890579, 10299870, 12014425, 14835772, 17396618, 29217646, 36888770, 46392235, 46506324, 53788343, 57404734, 77813559, 85098449, 93167027, 103601518, 104179065, 104636240, 123121565, 129833335, 135300429, 135651072, 138707135, 160967480, 163123087, 163826670, 177749495, 204359782, 223442821, 226973256, 241376193, 252156914
|
|||
ChEBI ID |
CHEBI:77317
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | HMG-CoA reductase (HMGCR) | Target Info | Modulator | [3] |
BioCyc | Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate) | |||
Superpathway of cholesterol biosynthesis | ||||
Mevalonate pathway | ||||
KEGG Pathway | Terpenoid backbone biosynthesis | |||
Metabolic pathways | ||||
Biosynthesis of antibiotics | ||||
AMPK signaling pathway | ||||
Bile secretion | ||||
NetPath Pathway | IL5 Signaling Pathway | |||
TGF_beta_Receptor Signaling Pathway | ||||
TSH Signaling Pathway | ||||
Panther Pathway | Cholesterol biosynthesis | |||
Pathwhiz Pathway | Steroid Biosynthesis | |||
WikiPathways | Statin Pathway | |||
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | ||||
Activation of Gene Expression by SREBP (SREBF) | ||||
SREBF and miR33 in cholesterol and lipid homeostasis | ||||
Integrated Breast Cancer Pathway | ||||
SREBP signalling | ||||
Cholesterol Biosynthesis |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2763). | |||
REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002306) | |||
REF 3 | The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A r... J Biol Chem. 1996 Jun 14;271(24):14376-82. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.